Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Astria Therapeutics ( (ATXS) ).
On October 14, 2025, Astria Therapeutics and BioCryst Pharmaceuticals announced an Agreement and Plan of Merger, where Astria will merge with a subsidiary of BioCryst, becoming a wholly owned subsidiary. The merger, set to close in the first quarter of 2026, involves a stock and cash transaction, with Astria’s shares being converted into BioCryst shares and cash. This merger will result in Astria’s delisting from Nasdaq, and it is subject to customary closing conditions, including regulatory approvals and stockholder consent. The merger aims to enhance BioCryst’s market position and operational capabilities, with financing commitments secured from Blackstone to support the transaction.
The most recent analyst rating on (ATXS) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Astria Therapeutics stock, see the ATXS Stock Forecast page.
Spark’s Take on ATXS Stock
According to Spark, TipRanks’ AI Analyst, ATXS is a Neutral.
Astria Therapeutics’ stock score reflects its status as a development-stage biotech company. The strong balance sheet provides financial stability, but the lack of revenue and increasing losses pose significant risks. Mixed technical indicators and valuation challenges further contribute to a cautious outlook.
To see Spark’s full report on ATXS stock, click here.
More about Astria Therapeutics
Astria Therapeutics operates in the biotechnology industry, focusing on pharmaceutical research and development, including drug discovery and clinical development activities.
Average Trading Volume: 334,684
Technical Sentiment Signal: Hold
Current Market Cap: $469M
Learn more about ATXS stock on TipRanks’ Stock Analysis page.